3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Thymus Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Myelodysplastic Syndromes
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Extensive Stage Small Cell Lung Carcinoma
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Cytopenia
1
Carcinoma, Transitional Cell
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
31
Gemcitabine
26
Nivolumab
20
atezolizumab
16
Cisplatin
15
avelumab
14
Carboplatin
12
Docetaxel
10
enfortumab vedotin
8
Magnetic Resonance Spectroscopy
8
durvalumab
7
Specimen Handling
7
Paclitaxel
7
Ipilimumab
6
toripalimab
5
pemigatinib
5
cabozantinib
5
vinflunine
4
sacituzumab govitecan
4
Taxes
4
Pemetrexed
4
tislelizumab
3
cabazitaxel
3
Standard of Care
3
Mitomycin
3
Injections
3
Everolimus
3
Albumin-Bound Paclitaxel
3
sapanisertib
2
olaparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Transitional Cell
×
epacadostat
×
Clear all
NCT04586244
2025-10-30
Optimus
Incyte Corporation
Phase 2
Terminated
30 enrolled
12 charts